GlassScriptPhysician profile
Asheesh Sood
NPI 1598727091
$6,356.96
in general payments reported to CMS, 2019-2025
29 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $179 · 2021: $499 · 2022: $662 · 2023: $1,287 · 2024: $1,385 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.98 | 2019-2025 | Mavyret, Linzess, Viberzi |
| E.R. Squibb & Sons, L.L.C. | $762.92 | 2021-2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $724.16 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $549.47 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $386.48 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $311.68 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $251.59 | 2019-2024 | Linzess |
| Qol Medical, LLC | $167.10 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $163.22 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $121.92 | 2021-2025 | Ocaliva |
| Horizon Therapeutics Plc | $116.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.64 | 2019 | |
| Teleflex LLC | $111.03 | 2024 | Urolift |
| Regeneron Healthcare Solutions, INC. | $100.39 | 2022-2025 | Dupixent |
| Medtronic, INC. | $90.61 | 2023-2024 | Interstim, Pillcam |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $89.31 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $83.41 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $82.86 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $81.71 | 2024-2025 | Voquezna |
| Sandoz INC. | $59.31 | 2023-2024 | Hyrimoz |
| Celgene Corporation | $56.83 | 2021-2022 | |
| Genzyme Corporation | $56.77 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $49.51 | 2022-2023 | Dificid |
| Ardelyx, INC. | $49.03 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $48.29 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $23.91 | 2025 | Rebyota |
| Boston Scientific Corporation | $21.11 | 2025 | Watchman Flx |
| Redhill Biopharma INC. | $19.38 | 2020 | |
| Endo Pharmaceuticals INC. | $14.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asheesh Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.